The marijuana capital markets have experienced a whirlwind over the past few years – and this year’s elections around the nation show little sign of affecting the capital markets no matter who comes out on top.
Historically, investors have shown high hopes for the cannabis industry, particularly in the wake of evolving state-level legalizations. Yet the capital markets have changed dramatically.
As of October, cannabis stocks such as the AdvisorShares Pure US Cannabis ETF (MSOS) are down more than 85% from their all-time highs.
Despite this sharp decline, the regulated U.S. marijuana market is larger than ever, growing from $27 billion in 2021 to an anticipated $32.1 billion by the end of 2024, according to the MJBiz Factbook.
A comprehensive, thoughtfully curated overview of the stories defining today's cannabis sector — breaking news, investigative features, expert commentary, and context-rich analysis to help you navigate events with clarity and confidence.
Home / Could Cannabis Capital Markets Thrive Next Year?
Could Cannabis Capital Markets Thrive Next Year?
The marijuana capital markets have experienced a whirlwind over the past few years – and this year’s elections around the nation show little sign of affecting the capital markets no matter who comes out on top.
Historically, investors have shown high hopes for the cannabis industry, particularly in the wake of evolving state-level legalizations. Yet the capital markets have changed dramatically.
As of October, cannabis stocks such as the AdvisorShares Pure US Cannabis ETF (MSOS) are down more than 85% from their all-time highs.
Despite this sharp decline, the regulated U.S. marijuana market is larger than ever, growing from $27 billion in 2021 to an anticipated $32.1 billion by the end of 2024, according to the MJBiz Factbook.
This item originally appeared on MJBizDaily. The rest of the story is available here.
MJBizDaily
Other featured articles
Germany’s Medical Cannabis Insurance Reform Descends Into Chaos as Regulators Turn on Each Other
By
Selling US Grown Flower to Europe: What the Margin Actually Says
By
Isreal Reopens Canadian Cannabis Dumping Case, This Time With a Route Around Its Finance Minister
By
New Report: Germany’s Cannabis Market Crosses €1.15bn as Reimbursement Era Ends
By
The science of THCV
By
Other featured Opinion articles
Why Medical Companies Win Rescheduling, Whatever Happens to Adult-Use
By
Who Really Benefits from Britain’s Medical Cannabis System?
By
Is the US Hemp Ban Punishing the Wrong People?
By
Cannabis at an Inflexion Point: A Structural Repricing Ahead
By
Europe’s Medical Cannabis Market Has Grown Up, Now Its Supply Chain Needs To
By
Share Article
The Briefing / Newsletter
Insights
you don't want
to miss.
A comprehensive, thoughtfully curated overview of the stories defining today's cannabis sector — breaking news, investigative features, expert commentary, and context-rich analysis to help you navigate events with clarity and confidence.
Related news
Germany’s Medical Cannabis Insurance Reform Descends Into Chaos as Regulators Turn on Each Other
By
Selling US Grown Flower to Europe: What the Margin Actually Says
By
Isreal Reopens Canadian Cannabis Dumping Case, This Time With a Route Around Its Finance Minister
By
New Report: Germany’s Cannabis Market Crosses €1.15bn as Reimbursement Era Ends
By
The science of THCV
By
Thailand Presses Medical-Only Cannabis Bill Toward Cabinet as Enforcement Drive Widens
By
US Hemp Industry Wins a Stay of Execution as Senate Delays Ban Until December
By
Spain’s Tobacco Crackdown Could Quietly Wipe Out Its Cannabis Clubs
By
‘Everything in Our Power’: German Patient Groups Fight to Overturn Cannabis Insurance Cuts
By